PolyPeptide Group AG (SWX:PPGN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 1.17B |
| Revenue (ttm) | 362.47M |
| Net Income (ttm) | -19.71M |
| Shares Out | 33.01M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | 61.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,812 |
| Average Volume | 107,445 |
| Open | 35.65 |
| Previous Close | 35.45 |
| Day's Range | 34.55 - 35.65 |
| 52-Week Range | 17.38 - 38.80 |
| Beta | 0.86 |
| RSI | 65.61 |
| Earnings Date | Aug 13, 2026 |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ... [Read more]
Full Company ProfileFinancial Performance
In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces Bankruptcy
New On The Block Polypeptide Group has announced it is conducting a review of strategic alternatives, including potential partnerships or a sale. The process, which is in coordination with majority sh...
KKR Explores Potential Acquisition of PolyPeptide Group
KKR Explores Potential Acquisition of PolyPeptide Group
PolyPeptide Shares Surge Amid Takeover Interest From EQT, KKR
PolyPeptide Group AG shares hit the highest level in more than three years, after people with knowledge of the matter said the Swiss contract drugmaker is attracting private equity takeover interest.
PolyPeptide Group AG (PLYGF) Full Year 2025 Earnings Call Highlights: Strong Revenue Growth and ...
PolyPeptide Group AG (PLYGF) Full Year 2025 Earnings Call Highlights: Strong Revenue Growth and Improved Margins Amid Strategic Shifts
PolyPeptide Group AG Earnings Call Transcript: H2 2025
2025 saw 16% revenue growth and a sharp EBITDA margin improvement, driven by metabolic therapeutics and capacity expansions. 2026 guidance targets 20%-25% revenue growth and mid to high teens EBITDA margin, with strong customer prepayments and no equity raise planned.
PolyPeptide Reports Strong Preliminary 2025 Results With Higher Revenue And Profit
(RTTNews) - PolyPeptide Group AG (PPGN.SW) on Monday reported preliminary results for the 2025 financial year, showing higher revenue and improved profitability compared with 2024. The company generat...
PolyPeptide Group AG (PLYGF) Reports FY Revenue of EUR 389M
PolyPeptide Group AG (PLYGF) Reports FY Revenue of EUR 389M
Lupin subsidiary forms long-term strategic alliance with PolyPeptide Group to strengthen global peptide supply chain
Lupin Manufacturing Solutions (LMS), a subsidiary of pharma giant Lupin Limited, has entered into a long-term strategic alliance with PolyPeptide...
PolyPeptide Group AG Earnings Call Transcript: H1 2025
Revenue grew 24% year-over-year in H1 2025, driven by commercial metabolics and strong cash flow. Guidance for 2025 was raised, with EBITDA margin expected at 8–12% and CapEx increased to $100 million. Capacity expansions and market momentum support confidence in 2028 targets.
PolyPeptide Group AG Earnings Call Transcript: H2 2024
2024 saw strong revenue and EBITDA growth, driven by commercial demand and capacity expansion, with the metabolic segment leading. The company confirmed its 2028 outlook to double revenues and approach a 25% EBITDA margin, while maintaining robust cash flow and customer support.
PolyPeptide Group AG Earnings Call Transcript: H1 2024
H1 2024 saw improved profitability, breakeven cash flow, and upgraded guidance to high single-digit revenue growth and mid-single digit EBITDA margin. The company targets doubling 2023 revenue and reaching a 25% EBITDA margin by 2028, supported by secured contracts and modular capacity expansion.